We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By closing this message, you are consenting to our use of cookies.


An open access journal

Join the Growing Conversation on Tumor Immunology

Tumor immunology focuses on the natural or therapy-induced recognition of cancers, as well as the intricate interplay between oncogenesis, inflammation and immunosurveillance. This high-profile, open access journal, OncoImmunology, focuses specifically on tumor immunology.

Recent progress has allowed for the first clinical demonstration (and FDA approval) of anticancer immunotherapies. There is also an ever-growing suspicion that—unexpectedly—many of the currently used chemotherapeutic agents depend in their efficacy on the active contribution of immune effectors. As a result, immunological biomarkers are becoming ever more important to determine the prognosis of cancers and to predict the efficacy of chemotherapies. There is also a strong rationale in favor of combining conventional anticancer therapies with immunotherapies.

OncoImmunology accepts high-profile submissions in the fundamental, translational and clinical areas of tumor immunology. Submissions dealing with solid or hematological cancers, inflammation, innate and acquired immune responses are welcome.

OncoImmunology publishes Original Research Articles, Brief Reports, Reviews, Commentaries and Meeting Reports in this area of research.

Why Publish in OncoImmunology?

  • Include yourself among high-impact, high-quality authors
  • Increase the impact of your research by making your article freely and permanently accessible worldwide
  • Immediately see the impact of your research made in the community: track downloads, citations and the Altmetric Score of your article on My Authored Works.


Visit Journal

Submission guidelines

Please read our Instructions for Authors for details on preparing your manuscript.

Submit your final manuscript online here.

MIATA Compliance

The immune monitoring community has recently established the consensus framework MIATA (“Minimal Information About T Cell Assays”) for reporting of T-cell assay results, which promote objective and thorough interpretation of data and the comparability of results. OncoImmunology supports and encourages the implementation of the MIATA guidelines

Editorial information

  • Editor-in-Chief: Lorenzo Galluzzi, University Paris Descartes, Paris, FR
  • Editor-in-Chief: Guido Kroemer, University of Paris Descartes, Paris, FR
  • Editor-in-Chief: Laurence Zitvogel, INSERM, Institut Gustave Roussy, Villejuif, FR